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Abstract: Recent guidelines for the treatment of hypertension have focused on the need for 
multiple medications to get most patients to goal blood pressure (BP). Two to three different 
classes of antihypertensive agents are frequently required, increasing the risk of poor compliance 
with therapy. Hence, the guidelines have recommended starting with combination therapy 
in patients with BP that is over 20 mm Hg systolic or 10 mm Hg diastolic above goal. The 
latest advance in treatment regimen has been the development of triple-therapy combinations 
of an angiotensin receptor blocker, amlodipine, and hydrochlorothiazide. We review the 
pathophysiologic rationale for such a combination and the efficacy, safety, and tolerability of 
the first triple therapy that has become available: valsartan + amlodipine + hydrochlorothiazide. 
Finally, we suggest that use of triple therapy could improve the accuracy of diagnosing resistant 
hypertension, an increasingly prevalent and severe condition, by enhancing adherence to treat-
ment and weeding out patients with pseudoresistance. This would allow for implementation of 
expensive and invasive workup only in those truly resistant patients in whom it is justified.
Keywords: combination therapy, compliance, hypertension control rates, resistant 
hypertension
Hypertension remains the most prevalent chronic disease in the developed world, and 
the number one reason for a patient to seek medical care. In addition, it is a major 
contributor to cardiovascular and renal morbidities and mortalities. Epidemiologic 
studies have demonstrated that even very small changes in population blood pressure 
(BP) (2 mm Hg) could have a major impact on ischemic heart disease or stroke 
mortality (7% and 10% decreases, respectively).1 Despite this recognition, control 
rates of hypertension continue to lag behind national goals.
The latest US data from the National Health and Nutrition Examination Survey2 
have shown a dramatic improvement in control of hypertension in the US over 
the last 10 years, with 50% of hypertensive subjects reaching goal BP of less than 
140/90 mm Hg. Unfortunately, this also means that 50% remain uncontrolled, and 
only 72% of all hypertensive subjects are treated. Reasons for poor control rates are 
multifactorial, including societal (eg, patient lack of understanding, compliance, 
or access to care or medications), physician inertia (failure to initiate or increase 
therapy for uncontrolled hypertension), and complications of treatment (side effects, 
inconvenience of multiple doses, interfering substances). The use of combination 





Report of the Joint National Committee on Prevention, 
  Detection,   Evaluation, and Treatment of High Blood Pressure 
(JNC7, 2003)3 was the first guideline to specifically advocate 
their use for these purposes. For subjects whose BP was at 
least 20/10 mm Hg above goal, the JNC7 recommended 
starting with a two-drug combination. The European guide-
lines of 2007 followed suit, also recommending combination 
treatment for those with elevated cardiovascular risk.4 Not 
only is such treatment likely to improve the rate at which 
BP goal is achieved5,6 but also it has been shown that more 
rapid control of BP improves adherence by enhancing trust 
in the physician–patient relationship.3,7
A further argument to support the use of combination 
therapy is the number of medications required to achieve 
goal BP in most patients. Publication of multiple large 
outcome trials in patients with hypertension over the last 
decade (eg, LIFE [Losartan Intervention for Endpoint 
  Reduction in Hypertension], ALLHAT [Antihypertensive 
and   Lipid-lowering Treatment to Prevent Heart Attack 
Trial], and ASCOT-BPLA [Anglo-Scandinavian Cardiac 
Outcomes Trial – Blood Pressure Lowering Arm]) has 
shown that most hypertensive subjects will require at least 
two   medications.8–10 Patients with increased cardiovascu-
lar or renal risk require 3.2 medications, on average, to 
achieve their lower goal BP.11 Recognition of this need has 
led to the marketing of multiple two-drug combinations, 
eg, thiazide diuretics with β-blockers, angiotensin-converting 
enzyme inhibitors (ACEIs), or angiotensin II type 1 receptor 
antagonists (ARBs); nondihydropyridine calcium channel 
blockers (CCBs) with ACEIs; and dihydropyridine (DHP) 
CCBs with ACEIs or ARBs. A number of these are approved 
by the US Food and Drug Administration (FDA) as first-line 
therapy for hypertension. The latest efforts have extended 
this approach to the development of three-drug combinations 
of ARB + DHPCCB + thiazide, eg, valsartan + amlodipine + 
hydrochlorothiazide. Although triple therapy with modern 
antihypertensive agents may seem to be an entirely new 
development, there is historical precedent for this approach. 
A product combining reserpine, hydralazine, and hydrochlo-
rothiazide has been available for decades, and the combina-
tion of these agents was shown to be safe and effective in 
one of the earliest Veterans Administration trials.12
The choice of which two agents to combine in one 
pill has relied on our current understanding of the many 
pathophysiological mechanisms underlying essential 
hypertension. Probably the best known of these mechanisms 
is the interaction between the renin–angiotensin–aldosterone 
system (RAAS) and sodium balance in determining BP. 
Studies carried out in the 1970s using the Goldblatt rat 
models of renovascular hypertension laid the foundation 
of our understanding of this interaction. In the two-kidney, 
one-clip (2K1C) model, renin secreted by the clipped kidney 
leads to renin-dependent hypertension. This is sustained 
long term via pressure natriuresis by the contralateral, 
nonclipped kidney, because preserved or reduced plasma 
volume maintains stimulation of continued renin secretion by 
the clipped kidney.13 In contrast, in the uninephrectomized, 
1K1C model, initial stimulation of renin secretion is soon 
inhibited by volume expansion because of absent pressure 
natriuresis, leading to diuretic-sensitive, renin-independent 
hypertension.14 This is the rationale for combining agents 
that are effective in renin-dependent hypertension, such 
as β-blockers or RAAS-blockers, with those that are more 
effective in renin-independent forms, such as diuretics. 
Whereas the vasodilating CCBs are efficacious in both 
renin-dependent and renin-independent hypertension, they 
stimulate renin release by renal vasodilation, natriuresis, and 
the lowering of BP itself, an effect that can be counteracted 
by combining them with an RAAS-blocker.15 Two-drug com-
binations have been available for some time and have been 
shown to improve adherence,16 outcomes,10,17 and overall 
rates of adverse events, and to reduce BP more promptly,18 
compared with their individual components.
Additional recent knowledge derived from clinical tri-
als was the most likely determinant for the selection of 
the three agents combined in the first triple-therapy pill 
released in the US: valsartan + amlodipine + hydrochlorothiazide. 
The renin-dependent and -independent components of BP 
elevation are addressed by the ARB and the diuretic com-
ponents of this combination, respectively, whereas the CCB 
amlodipine provides potent antihypertensive action for all 
  subjects. Moreover, there is proof from clinical trials that 
the ARB valsartan is effective in the treatment of high-risk 
hypertension (VALUE [Valsartan Antihypertensive Long-term 
Use   Evaluation] trial),19 congestive heart failure   (Val-HeFT 
[Valsartan Heart Failure Trial]),20 and ischemic heart disease 
  (VALIANT   [Valsartan in Acute Myocardial Infarction Trial]).21 
F  urthermore, as with all ARBs, this agent exhibits adverse 
event rates that are essentially indistinguishable from placebo. 
Amlodipine was more effective than valsartan at reducing 
the secondary outcomes of myocardial infarction and stroke 
in VALUE, owing largely to more rapid lowering of BP.19 
The concern of worsening heart failure with DHPCCBs due to 
reflex sympathetic activation by vasodilation was dispelled for 
amlodipine years ago in the PRAISE   (Prospective Randomized 




Antihypertensive effectiveness of valsartan + amlodipine + hydrochlorothiazide
potential adverse effect of amlodipine on progression of renal 
disease via afferent arteriolar vasodilatation and glomerular 
hyperfiltration, as suggested in the AASK23 (African American 
Study of Kidney Disease and Hypertension) trial, should be 
attenuated by the concomitant efferent arteriolar dilatation 
by the RAAS-blocker. Finally, thiazide-induced stimula-
tion of renin release potentiates the effect of the ARB in the 
combination, whereas, conversely, blockade of the proinflam-
matory and pro-oxidant effects of angiotensin II by the ARB 
contributes to attenuation of the potential adverse metabolic 
effects of this diuretic.24
The efficacy and safety of this triple combination were 
demonstrated by double-blind comparison of maximum usual 
doses of the three-drug regimen to each of the three possible 
two-drug combinations of its constituents in 4285 subjects 
with stage 2 hypertension.25 Following the initial 2–4 weeks of 
treatment on the lower dosages, patients were titrated to maxi-
mal doses of the dual or triple   combinations. After 8 weeks, 
triple therapy produced significantly greater reductions in 
systolic (6.2–8.2 mm Hg) and diastolic (3.3–5.3 mm Hg) 
BP and greater rates of control (71% vs 45%–54%) com-
pared with each of the dual-combination therapies. These 
effects were independent of age, gender, race, ethnicity, or 
baseline BP.25 In a secondary analysis, triple therapy was 
shown to reduce BP faster and with a greater effect in those 
with higher baseline systolic BP, without increasing adverse 
effects.26 A different design was employed in a trial of stage 
2 hypertension in black patients. They were initially treated 
with amlodipine monotherapy or with the dual valsartan + 
amlodipine combination. Hydrochlorothiazide, if needed to 
achieve systolic BP , 130, was added after 8 weeks. The 
resulting triple-therapy group sustained greater BP reduction 
compared with those who ultimately received amlodipine + 
hydrochlorothiazide dual therapy.27
The valsartan + amlodipine + hydrochlorothiazide triple-
therapy combination is not FDA approved for first-line use in 
hypertension. It is indicated for use in patients who remain 
uncontrolled on any two of the component classes. This com-
bination does not worsen either hypokalemia or hyperkalemia 
compared with the approved valsartan + hydrochlorothiazide 
combination. In addition, rates of edema are lower with 
the triple combination than with the approved valsartan + 
amlodipine dual therapy,25 most likely reflecting combined 
effects of postcapillary vasodilation by valsartan and volume 
contraction by hydrochlorothiazide. The only absolute con-
traindication to its use, as for any preparation containing an 
RAAS-blocker, is pregnancy. There is no evidence of the 
need for dose adjustment in the elderly.
There have been no published comparisons of this 
triple therapy with a similar regimen employing a different 
ARB. However, a comparison of treatment with valsartan + 
amlodipine + hydrochlorothiazide with losartan + hydrochlo-
rothiazide treatment in patients with stage 2 hypertension was 
presented at the American Society of Hypertension meeting 
in May 2010. In this study, the triple therapy showed faster 
and greater BP reduction than did the losartan-based dual 
therapy. In addition, subjects who were initially randomized 
to dual-therapy arms and subsequently switched to triple 
therapy sustained the expected additional decrease in BP 
and increase in control rates.28
Results of treatment with another triple-therapy combina-
tion using the ARB olmesartan with amlodipine and hydro-
chlorothiazide were recently published.29 In this study, 2492 
patients with stage 2 hypertension were initially randomized 
to one of the three possible highest-dose dual combinations for 
2–4 weeks. Half of them were later switched to the highest-dose 
triple-therapy combination for a further 8 weeks. Triple therapy 
produced an additional 7.1–9.6 mm Hg reduction in systolic BP 
and a 3.8–6.7 mm Hg reduction in diastolic BP compared with 
dual therapy, with increased control rates (70% vs 41%–53%) 
and without an increase in adverse effects.29
In summary, triple combinations of an ARB with 
amlodipine and hydrochlorothiazide have been shown to 
be safe and effective in lowering BP in moderate to severe 
hypertension.
We have suggested that there may be a role for triple 
therapy in making an accurate diagnosis of resistant 
  hypertension,30 which is a major problem that is increasing in 
prevalence. Resistant hypertension is defined as the inability 
to achieve risk factor-adjusted goal BP (less than 140/90 in 
uncomplicated hypertensive patients, and less than 130/80 in 
those with diabetes or confirmed cardiovascular or chronic 
kidney disease), despite optimal doses of three agents from 
different families, one of which is a diuretic.31 Diuretics not 
only potentiate the action of most other antihypertensive thera-
pies but also are uniquely efficacious in the 50% of hyperten-
sive patients with salt-sensitive BP.31,32 These subjects are at 
increased cardiovascular risk, independent of the severity of 
their hypertension,33 via mechanisms that are not yet com-
pletely understood.34,35 The current prevalence of resistant 
hypertension is estimated at 20%–30% of all hypertensive 
patients. It is more common in certain subgroups (eg, elderly, 
black, obese, diabetic, and those with hypertensive heart 
disease and chronic kidney disease)31 who have a higher 
prevalence of salt sensitivity of BP, and is likely to increase 





Making an accurate diagnosis of resistant hypertension is 
of the utmost importance in order to avoid unnecessary, costly, 
and invasive workup for an overlooked cause (such as second-
ary hypertension) in subjects who may have pseudoresistance. 
Recognized causes for the latter include lack of compliance 
owing to complex medication regimens in patients with hyper-
tension and multiple comorbidities, or discouragement by the 
lack of success of BP control with slow therapeutic regimens 
employing a stepwise approach to the addition of drugs or 
dose escalation. We have suggested that decreased pill burden 
and rapid escalation from two-drug regimens (in separate or 
combined pills) to a single-pill, triple-therapy approach may 
diminish pseudoresistance by increasing compliance and 
adherence36 with ensuing control of BP in these subjects. This 
would allow for quicker and more accurate identification of a 
smaller number of subjects with truly resistant hypertension, 
in whom an aggressive workup may be indicated appropri-
ately, despite its risks and costs.
Conclusions
The combination valsartan + amlodipine + hydrochlorothiazide 
has been shown to be safe and effective in lowering BP across 
a broad spectrum of hypertensive populations (young and 
old, male and female, black and white) with moderate to 
severe hypertension. By combining agents with differing 
antihypertensive mechanisms, this therapy reduces side 
effects of the individual classes while enhancing their 
actions. Control rates are improved over dual therapy and are 
achieved more rapidly, thereby enhancing compliance. Our 
contention is that use of such a triple-therapy combination 
could lead to better recognition of truly resistant hyperten-
sion, which is becoming an increasingly prevalent problem 
as society ages and becomes more obese.
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